EP4682143A1 — Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof
Assigned to Convalife Pharmaceuticals Co Ltd · Expires 2026-01-21 · 0y expired
What this patent protects
Disclosed in the present invention are a pharmaceutical composition containing an EGFR inhibitor, and a preparation method therefor and the use thereof. The pharmaceutical composition contains particles, wherein the particles contain the following components in mass fraction: 30%…
USPTO Abstract
Disclosed in the present invention are a pharmaceutical composition containing an EGFR inhibitor, and a preparation method therefor and the use thereof. The pharmaceutical composition contains particles, wherein the particles contain the following components in mass fraction: 30%-45% of anhydrous neratinib maleate, 7%-28% of copovidone, 25%-48% of a filler, 1.0%-8.0% of a disintegrant, 0.5%-4.0% of a glidant and 0.5%-4.0% of a lubricant. The pharmaceutical composition of the present invention has good stability and in-vivo biological activity equivalent to that of a reference preparation, and has a good application prospect.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.